Atara Biotherapeutics (ATRA) Competitors $11.90 -0.21 (-1.77%) As of 01:29 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATRA vs. ORIC, ANNX, LFCR, MNPR, VOR, ACB, CRDF, EDIT, ZYBT, and DBVTShould you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Oric Pharmaceuticals (ORIC), Annexon (ANNX), Lifecore Biomedical (LFCR), Monopar Therapeutics (MNPR), Vor Biopharma (VOR), Aurora Cannabis (ACB), Cardiff Oncology (CRDF), Editas Medicine (EDIT), Zhengye Biotechnology (ZYBT), and DBV Technologies (DBVT). These companies are all part of the "pharmaceutical products" industry. Atara Biotherapeutics vs. Its Competitors Oric Pharmaceuticals Annexon Lifecore Biomedical Monopar Therapeutics Vor Biopharma Aurora Cannabis Cardiff Oncology Editas Medicine Zhengye Biotechnology DBV Technologies Atara Biotherapeutics (NASDAQ:ATRA) and Oric Pharmaceuticals (NASDAQ:ORIC) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk. Which has more volatility and risk, ATRA or ORIC? Atara Biotherapeutics has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, Oric Pharmaceuticals has a beta of 1.54, meaning that its share price is 54% more volatile than the S&P 500. Is ATRA or ORIC more profitable? Oric Pharmaceuticals has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -7.83%. Atara Biotherapeutics' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Atara Biotherapeutics-7.83% N/A -14.51% Oric Pharmaceuticals N/A -51.14%-46.29% Which has better earnings and valuation, ATRA or ORIC? Atara Biotherapeutics has higher revenue and earnings than Oric Pharmaceuticals. Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Atara Biotherapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtara Biotherapeutics$128.94M0.55-$85.40M-$3.72-3.20Oric PharmaceuticalsN/AN/A-$127.85M-$1.87-5.46 Does the media prefer ATRA or ORIC? In the previous week, Oric Pharmaceuticals had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Oric Pharmaceuticals and 3 mentions for Atara Biotherapeutics. Oric Pharmaceuticals' average media sentiment score of 1.42 beat Atara Biotherapeutics' score of 0.90 indicating that Oric Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atara Biotherapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts recommend ATRA or ORIC? Atara Biotherapeutics currently has a consensus target price of $20.00, suggesting a potential upside of 68.12%. Oric Pharmaceuticals has a consensus target price of $18.57, suggesting a potential upside of 81.82%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Atara Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atara Biotherapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83Oric Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders hold more shares of ATRA or ORIC? 70.9% of Atara Biotherapeutics shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 4.0% of Atara Biotherapeutics shares are held by company insiders. Comparatively, 6.8% of Oric Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. SummaryOric Pharmaceuticals beats Atara Biotherapeutics on 10 of the 16 factors compared between the two stocks. Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRA vs. The Competition Export to ExcelMetricAtara BiotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.90M$3.04B$5.59B$9.59BDividend YieldN/A2.39%4.71%4.03%P/E Ratio-3.2023.9130.1220.53Price / Sales0.55323.08448.5398.76Price / CashN/A42.5936.0158.40Price / Book-0.708.538.415.79Net Income-$85.40M-$55.06M$3.25B$259.21M7 Day Performance-2.73%-1.47%-1.73%-2.29%1 Month Performance54.09%16.00%8.41%9.09%1 Year Performance21.02%4.16%36.52%15.39% Atara Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRAAtara Biotherapeutics4.5068 of 5 stars$11.90-1.8%$20.00+68.1%+25.8%$70.90M$128.94M-3.20330ORICOric Pharmaceuticals4.5769 of 5 stars$11.18-2.3%$18.57+66.1%-4.6%$974.97MN/A0.0080News CoveragePositive NewsANNXAnnexon2.4733 of 5 stars$2.49-0.8%$12.50+402.0%-58.3%$275.38MN/A0.0060LFCRLifecore Biomedical1.4519 of 5 stars$7.33-1.3%$8.00+9.1%+12.5%$275.10M$128.26M0.00690MNPRMonopar Therapeutics2.4117 of 5 stars$43.40-3.5%$60.00+38.2%+1,118.5%$275MN/A0.0010Positive NewsVORVor Biopharma0.725 of 5 stars$2.42+10.0%N/AN/A$274.91MN/A0.00140ACBAurora Cannabis0.2056 of 5 stars$4.78-1.2%N/A-23.0%$272.23M$246.72M80.671,130News CoverageUpcoming EarningsCRDFCardiff Oncology1.2444 of 5 stars$3.73-6.0%$11.70+213.7%+9.2%$264.11M$680K0.0020News CoveragePositive NewsEarnings ReportOptions VolumeGap UpEDITEditas Medicine4.0047 of 5 stars$2.96-6.0%$4.70+58.8%-53.5%$263.70M$32.31M0.00230News CoverageUpcoming EarningsZYBTZhengye BiotechnologyN/A$5.75+3.6%N/AN/A$261.77M$25.53M0.00278Positive NewsGap DownDBVTDBV Technologies3.6749 of 5 stars$9.86+4.2%$14.75+49.7%+98.5%$258.97M$4.15M0.0080Earnings Report Related Companies and Tools Related Companies ORIC Alternatives ANNX Alternatives LFCR Alternatives MNPR Alternatives VOR Alternatives ACB Alternatives CRDF Alternatives EDIT Alternatives ZYBT Alternatives DBVT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATRA) was last updated on 7/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATRA Stock Alerts